Publication
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22722830
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS A146T1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID7176identified a KRAS(A146T) mutation after four passages in increasing concentrations of cetuximab (20 nM and higher; These cells were indeed resistant to the drug. These mutations that arise are the res… (full text at CIViC) PMID 22722830 · Misale et al., 2012 · Open in CIViC | civic |
| KRAS G12R1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 4 | accepted | EID3989In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutat… (full text at CIViC) PMID 22722830 · Misale et al., 2012 · Open in CIViC | civic |
| KRAS G13D1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | — | accepted | EID3878In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wil… (full text at CIViC) PMID 22722830 · Misale et al., 2012 · Open in CIViC | civic |
| KRAS Mutation1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 3 | submitted | EID6464This study shows that KRAS mutations such as G12D, G13D and KRAS amplification are frequent drivers of acquired resistance to cetuximab in colorectal cancers. KRAS mutant clones can be detected throug… (full text at CIViC) PMID 22722830 · Misale et al., 2012 · Open in CIViC | civic |
| KRAS Q61H1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Supports Resistance | — | accepted | EID3862In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a par… (full text at CIViC) PMID 22722830 · Misale et al., 2012 · Open in CIViC | civic |